Jefferies Raises Liquidia Target to $60 After $133M Q1 and $53M Profit
Jefferies raised its price target for Liquidia to $60 following Q1 2026 revenues of $133 million, EPS of $0.52 and net income of $53 million. Strong YUTREPIA adoption with 4,500 patient prescriptions and 980 prescribing physicians spurred a 25.6% stock surge to a 52-week high of $53.93.
1. Strong Q1 2026 Financial Performance
Liquidia reported Q1 2026 revenues of $133.0 million, a jump from $3.0 million in Q1 2025, delivering EPS of $0.52 versus a $0.45 loss per share a year earlier. Net income reached $53.0 million, marking the third consecutive profitable quarter and underscoring a major turnaround.
2. Jefferies Raises Price Target to $60
Analyst Amy Li boosted the price target from $57 to $60 after the quarter’s results, reflecting confidence in Liquidia’s growth trajectory. The new target was set when the stock traded at about $53.13, signaling potential upside of more than 12%.
3. YUTREPIA Adoption Drives Stock Surge
YUTREPIA generated high market traction with roughly 4,500 unique patient prescriptions and 3,750 treatment starts as of April 30, while 980 physicians now prescribe the drug, including a 25% rise in heavy prescribers since February. This momentum fueled a 25.6% one-day stock surge to a 52-week high of $53.93 and lifted market capitalization to $4.68 billion.